The partisan divide in the United States throughout the COVID-19 pandemic has stretched beyond differences in attitudes about masking, social distancing and vaccines. According to a new study led by a University of Maryland researcher, it also is tied to a clear difference in mortality rates from the virus. In the study, published today in Health
Since June 2020, 214 human cases of COVID-19 have been identified in Denmark with SARS-CoV-2 variants associated with farmed minks, including 12 cases with a unique variant, reported on 5 November. All 12 cases were identified in September 2020 in North Jutland, Denmark. The cases ranged in age from 7 to 79 years, and eight
The national health commission said it would start to include asymptomatic cases in its Covid-19 statistics in move to address public concern Classified government data has suggested that silent carriers could make up around a third of cases Source South China Morning Post China will include asymptomatic coronavirus carriers in its daily figures from Wednesday,
China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the Covid-19 (coronavirus) outbreak, according to an official today Favipiravir, the influenza drug which was approved for clinical use in Japan in 2014, has shown no obvious adverse reactions in the clinical trial, said Zhang Xinmin, director
A fast-track vaccine will be tried on people soon but it uses an unproven technology. During a press opportunity on March 2, a dozen biotech company executives joined President Donald Trump around the same wooden table where his cabinet meets. As each took a turn saying what they could add to the fight against the spreading
Mesoblast today announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. The Company is in active discussions with various government and regulatory authorities, medical institutions and pharmaceutical companies to
An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory illness COVID-19 yielded an estimate of 5.1 days for the median disease incubation period, according to a new study led by researchers at Johns Hopkins Bloomberg School of Public Health. This median time from exposure to onset of
This helps to explain the rapid and efficient way in which the virus has spread around the world. At the same time, the study suggests that while people with mild infections can still test positive by throat swabs for days and even weeks after their illness, those who are only mildly sick are likely not still infectious
The epidemiological features of the coronavirus disease 2019 (Covid-19) outbreak are described and evaluated the impact of non-pharmaceutical interventions on the epidemic in Wuhan, China. Individual-level data on 25,961 laboratory-confirmed Covid-19 cases reported through February 18, 2020 were extracted from the municipal Notifiable Disease Report System. Based on key events and interventions, the epidemic was
Takeda Pharmaceutical Co said on Wednesday it was developing a drug for high-risk patients infected with the new coronavirus, joining several other drugmakers seeking to develop a treatment for an illness that has killed over 3,000 people. The Japanese firm said it was working on a plasma-derived therapy which had previously been shown to be
